

## South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, March 8, 2019

1:00 – 3:00 pm CT

### Members and DSS Staff

Michelle Baack, MD		Kelley Oehlke, PharmD	X
Dana Darger, RPh		Lenny Petrik, PharmD	X
James Engelbrecht, MD	X	Timothy Soundy, MD	
Deidre Van Gilder, PharmD	X	Mike Jockheck, DSS Staff	X
Mikal Holland, MD		Sarah Akers, DSS Staff	
Richard Holm, MD		Bill Snyder, DSS Staff	X
Bill Ladwig, RPh, Chair	X		

### Administrative Business

Ladwig called the meeting to order at 1:10 PM. The minutes of the December meeting were presented. Engelbrecht questioned if PPI criteria changes from the previous meeting had been disseminated to providers. Changes were implemented, but Jockheck commented that he would add notice regarding the criteria changes to the DSS website for the providers. Oehlke made a motion to approve. Van Gilder seconded the motion. Motion was approved unanimously.

### Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from October 1, 2018 to December 31, 2018. A total of 1,506 PAs were reviewed of which 327 requests (22%) were received via telephone and 1,177 requests (78%) were received via fax. Engelbrecht questioned the need for PA if approval rate is 99%. An in-depth review of PAs with over 95% approval to be provided at the next meeting to determine PA necessity.

### Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from October 1, 2018 to December 31, 2018. The top five therapeutic classes were atypical antipsychotics, selective beta-2 adrenergic agonists, anticonvulsants, and amphetamines. The top 15 therapeutic classes make up 31.69% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 28.81% of total claims. Van Gilder commented generics' paid/Rx amount seemed higher than the previous quarter. Jockheck confirmed Indian Health Services (IHS) claims were included which are processed on an encounter fee schedule. IHS utilization data will be excluded henceforth. Committee also reviewed Fiscal Year PMPM figures. Ladwig commented on the corrections for years 2017 and 2018. Jockheck explained that moving to the new system with OptumRx resulted in the correction.

### Old Business

Committee reviewed CGRP utilization comparing 3Q18 vs 4Q18. Committee requested to review utilization again at the next meeting.

Committee reviewed CiproDex utilization for 4Q18. Van Gilder commented on prescribers such as dentist, chiropractors, LPN, and students prescribing out of scope; in addition to prescribers from outside South Dakota. Jockheck commented that prescribers for IHS could be from other states.

Engelbrecht requested to review 1Q19 CiproDex utilization data at the next meeting. IHS data will be removed.

Engelbrecht commented on Dupixent's fax form and requested asthma diagnosis to be included. Updated fax form and clinical information to be brought back to the next meeting.

Ladwig requested an outcomes report for opioid edits that went into effect in 2018.

#### **New business**

After reviewing the ADD/ADHD utilization, committee requested utilization to be brought back to the next meeting. Utilization will be separated out by child vs adults.

The committee reviewed Consensi clinical information. There was no public comment. The committee requested to monitor utilization for this drug.

The committee reviewed Orilissa clinical information. Michael Gonzalez from AbbVie spoke regarding Orilissa. The committee requested to monitor utilization for this drug. Ladwig inquired what other Medicaid states are doing with this drug.

The committee reviewed clinical information on new immunomodulators. PAs will be added to new immunomodulators; including new and expanded indications for others. If a new indication is not straight forward, committee would like to review those.

The next meeting is scheduled for June 21, 2019. Tentative meeting date for September is September 27, 2019. Van Gilder made a motion to adjourn the P&T committee meeting. Oehlke seconded the motion. The motion passed unanimously and the meeting adjourned at 2:15 PM.